Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2025 | $28.00 | Strong Buy | Raymond James |
| 12/9/2025 | $16.00 | Equal Weight | Barclays |
| 2/14/2025 | $23.00 | Overweight | Cantor Fitzgerald |
| 5/3/2024 | $24.00 | Buy | Stifel |
| 1/5/2024 | $23.00 → $26.00 | Buy | Needham |
| 8/9/2023 | $28.00 | Buy | H.C. Wainwright |
| 5/11/2023 | In-line → Outperform | Evercore ISI | |
| 3/13/2023 | $21.00 | Buy | Craig Hallum |
Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination
Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer
424B5 - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
S-3ASR - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the pricing of an underwritten public offering of 6,875,000 shares of its common stock and pre-funded warrants to purchase 1,250,078 shares of common stock. The shares of common stock are being sold to the public at a price of $16.00 per share and the pre-funded warrants are being sold at a price of $15.999 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded war
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In addition, Phathom intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of the securities offered in the public offering. There can be no assu
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.Preliminary Fourth Quarter 2025 Financial Results For the three months ended December 31, 2025, Phathom expects to report: Net revenues of approximately $57 million to $58 millionGAAP operating expenses of approximately $59 million to $61 millionNon-GAAP operating expenses of approximately $51 million to $53 million, which excludes approximately $8
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
Raymond James initiated coverage of Phathom Pharmaceuticals with a rating of Strong Buy and set a new price target of $28.00
Barclays initiated coverage of Phathom Pharmaceuticals with a rating of Equal Weight and set a new price target of $16.00
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals with a rating of Overweight and set a new price target of $23.00
Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellenceAppointment strengthens Phathom's leadership team and ability to execute its growth strategy in GI FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Sanjeev Narula as Chief Financial and Business Officer. "We welcome Sanjeev to Phathom's leadership team at this important stage of our growth," said Steve Basta, President
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Anne Marie Cook as Chief Legal Officer and Corporate Secretary, the Company's Board of Directors has approved the grant of inducement awards. On June 23, 2025, the Compensation Committee of the Company's Board of Directors granted inducement awards to Ms. Cook under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Ms. Cook was granted a non-qualified stock option to purchase
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance, commercial law, regulatory compliance, strategic transactions and legal strategy. Ms. Cook most recently served as Senior Vice President, General Counsel of Sage Therapeutics, Inc. and previously se
Over 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarterFull-year 2025 revenue guidance updated to $170–$175 million; company expects to achieve operating profitability in 2026Management to host conference call today, October 30, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the third q
Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 30, 2025, to report its third quarter 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A
Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to $175 millionCompany remains focused on path to profitability in 2026Management to host conference call today, August 7, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter ended June 30, 2025, and provided business updates. "The second quarter marked
SC 13G - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)
SC 13D/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)
SC 13D/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)